143 related articles for article (PubMed ID: 33306631)
1. Prognostic value of imaging-based parameters in patients with intermediate-stage hepatocellular carcinoma undergoing transarterial radioembolization.
Puranik AD; Rangarajan V; Gosavi A; Shetty N; Gala K; Kulkarni S; Mohite A; Patkar S; Goel M; Shrikhande SV; Ramaswamy A; Ostwal V; Purandare NC; Agrawal A; Shah S
Nucl Med Commun; 2021 Mar; 42(3):337-344. PubMed ID: 33306631
[TBL] [Abstract][Full Text] [Related]
2.
Jreige M; Mitsakis P; Van Der Gucht A; Pomoni A; Silva-Monteiro M; Gnesin S; Boubaker A; Nicod-Lalonde M; Duran R; Prior JO; Denys A; Schaefer N
Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1215-1222. PubMed ID: 28233086
[TBL] [Abstract][Full Text] [Related]
3. Total Lesion Glycolysis on 18F-FDG PET/CT Is a Better Prognostic Factor Than Tumor Dose on 90Y PET/CT in Patients With Hepatocellular Carcinoma Treated With 90Y Transarterial Radioembolization.
Hwang SH; Hong HS; Kim D; Kim GM; Lee HW; Lee M; Kim DY; Park MA; Yun M
Clin Nucl Med; 2022 Jun; 47(6):e437-e443. PubMed ID: 35384891
[TBL] [Abstract][Full Text] [Related]
4. Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers.
Takeuchi S; Rohren EM; Abdel-Wahab R; Xiao L; Morris JS; Macapinlac HA; Hassan MM; Kaseb AO
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):969-978. PubMed ID: 27942837
[TBL] [Abstract][Full Text] [Related]
5. Streamlining radioembolization in UNOS T1/T2 hepatocellular carcinoma by eliminating lung shunt estimation.
Gabr A; Ranganathan S; Mouli SK; Riaz A; Gates VL; Kulik L; Ganger D; Maddur H; Moore C; Hohlastos E; Katariya N; Caicedo JC; Kalyan A; Lewandowski RJ; Salem R
J Hepatol; 2020 Jun; 72(6):1151-1158. PubMed ID: 32145255
[TBL] [Abstract][Full Text] [Related]
6. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
Ding CY; Guo Z; Sun J; Yang WP; Li TR
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
[No Abstract] [Full Text] [Related]
7. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.
Spreafico C; Sposito C; Vaiani M; Cascella T; Bhoori S; Morosi C; Lanocita R; Romito R; Chiesa C; Maccauro M; Marchianò A; Mazzaferro V
J Hepatol; 2018 Apr; 68(4):724-732. PubMed ID: 29331342
[TBL] [Abstract][Full Text] [Related]
8. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative 18F-FDG PET/CT in Patients With Very Early and Early Hepatocellular Carcinoma.
Hwang SH; Lee JW; Cho HJ; Kim KS; Choi GH; Yun M
Clin Nucl Med; 2017 Jan; 42(1):34-39. PubMed ID: 27775949
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with Barcelona Clinic Liver Cancer stages 0 and A hepatocellular carcinomas: a multicenter retrospective cohort study.
Hyun SH; Eo JS; Lee JW; Choi JY; Lee KH; Na SJ; Hong IK; Oh JK; Chung YA; Song BI; Kim TS; Kim KS; Moon DH; Yun M
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1638-45. PubMed ID: 26936852
[TBL] [Abstract][Full Text] [Related]
11. Metabolic activity assessment by
Kim DY; Lee HW; Kang W; Kim GM; Won JY; Yun M
J Gastroenterol Hepatol; 2021 Jun; 36(6):1679-1684. PubMed ID: 33226706
[TBL] [Abstract][Full Text] [Related]
12. The predictive value of metabolic tumor volume on FDG PET/CT for transarterial chemoembolization and transarterial chemotherapy infusion in hepatocellular carcinoma patients without extrahepatic metastasis.
Lee JW; Yun M; Cho A; Han KH; Kim DY; Lee SM; Lee JD
Ann Nucl Med; 2015 Jun; 29(5):400-8. PubMed ID: 25652647
[TBL] [Abstract][Full Text] [Related]
13. 90Y Radioembolization Lung Shunt Fraction in Primary and Metastatic Liver Cancer as a Biomarker for Survival.
Xing M; Lahti S; Kokabi N; Schuster DM; Camacho JC; Kim HS
Clin Nucl Med; 2016 Jan; 41(1):21-7. PubMed ID: 26222534
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of pretreatment PET/CT lean body mass-corrected parameters in patients with hepatocellular carcinoma.
Sun M; Zhang G; Guo J; Hao S; Wang Z; Fan G
Nucl Med Commun; 2018 Jun; 39(6):564-571. PubMed ID: 29634658
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of Volumetric Parameters Measured by Pretreatment 18F FDG PET/CT in Patients With Cutaneous Malignant Melanoma.
Son SH; Kang SM; Jeong SY; Lee SW; Lee SJ; Lee J; Ahn BC
Clin Nucl Med; 2016 Jun; 41(6):e266-73. PubMed ID: 27055144
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
17. Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis.
Kokabi N; Camacho JC; Xing M; El-Rayes BF; Spivey JR; Knechtle SJ; Kim HS
Cancer; 2015 Jul; 121(13):2164-74. PubMed ID: 25847227
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
[TBL] [Abstract][Full Text] [Related]
19. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R
Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011
[TBL] [Abstract][Full Text] [Related]
20. The role of volumetric and textural analysis of pretreatment 18F-fluorodeoxyglucose PET/computerized tomography images in predicting complete response to transarterial radioembolization in hepatocellular cancer.
Karahan Şen NP; Alataş Ö; Gülcü A; Özdoğan Ö; Derebek E; Çapa Kaya G
Nucl Med Commun; 2022 Jul; 43(7):807-814. PubMed ID: 35506284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]